Cynatas managing director Dr Ross Macdonald will present at Proactives CEO Sessions in Sydney on February 3 and Melbourne on February 4.

() is focused on using its proprietary Cymerusplatform technology to develop commercially scalable cellular therapeutic products to treat serious chronic disorders.

The trademark Cymerus refers to the patented process of generating cell-based products from intermediate cells

At present, Cynata is focused on the production of mesenchymal stem cell (MSC)-based products using the Cymerus technology.

An example of an MSC product is CYP-001, targeting graft-versus-host-disease (GvHD) for which a Phase I clinical trial has been completed.

During 2019, Fujifilm did a licensing deal with Cynata for CYP-001 and GvHD for a US$3 million upfront payment and future payments of up to US$43 million.

Cynata continues to focus on early commercialisation of Cynatas Cymerus MSC products and is in active commercial discussions for numerous therapeutic targets.

During calendar year 2020, Cynata plans tobeprogressing to three Phase II trials in for GvHD (funded by Fujifilm), CLI, and osteoarthritis.

The company also continues to investigate the therapeutic potential in numerous additional target areas.

It is worth noting the Cymerus process has a number of key advantages including being only platform in the world able to produce commercial quantities of MSCs from a single source.

Five companies will present at the Sydney and Melbourne events, including (), () and ().

The Sydney session will also include ().

Register now for the CEO Sessions

Sydney event, Monday, February 3

Melbourne event, Tuesday, February 4

See the article here:
Cynata Therapeutics to talk stem cell therapies at Proactive"s CEO Sessions - Proactive Investors Australia